

List of Figures

Fig. No.	Caption	Page No.
1.1	Human circadian rhythm dependent secretion of hormones in a pulsatile manner	4
1.2	Human circadian rhythm dependent aggravation of chronological diseases/disorders	5
5.1	Overlaid UV spectra of 2-25 µg/mL PRS in water	71
5.2	UV calibration curve of PRS (2-25 µg/mL)	72
5.3	Overlain HPLC chromatograms of 1-20 µg/mL PRS	75
5.4	HPLC calibration curve of PRS (1-20 µg/mL)	76
5.5	Drug release profile of PRS core tablet in pH 6.8 phosphate buffer; basket apparatus; 100 rpm; 500 mL; 37.0±0.5°C.	97
5.6	Effect of type and amount of lubricants and/or glidants on lag time of compression-coated EC tablets.	99
5.7	Typical dissolution pattern of CCTs depicting distinct lag time followed by burst release profile	100
5.8	The SEM images of CCTs prepared from (A) unlubricated EC; (B) colloidal SiO ₂ (0.50% w/w) and MgSt (0.25% w/w) lubricated blend; and (C) talc (1.00% w/w) and sodium stearyl fumarate (SSF) (0.50% w/w) lubricated blend	101
5.9	A holistic diagram illustrating the effect of lubricants/glidants on lag time of compression-coated EC tablets	103
5.10	(A) The photographs showing fast rupturing of 1.00% w/w colloidal SiO ₂ lubricated CCT, (B) the photographs of CCT before and after drug release study	105
5.11	Effect of MgSt concentration on lag time of compression-coated EC tablets	107
5.12	Effect of several hydrophilic additives on lag time of compression-coated EC tablets	109
5.13	Drug release profiles of six individual units of various EC based CCTs having different type and/or amount of HPMC in the outer coat	112
5.14	Effect of type and amount of HPMC on lag time of EC based CCTs	113
5.15	The SEM images of several EC based CCTs, having different MW HPMC at 20% w/w concentration in outer coat, before and after drug release study	116
5.16	Effect of HPMC MWs and their concentrations on lag time of EC based CCTs	117
5.17	Effect of HPMC MWs and their concentrations on lag time variability (% RSD) of EC based CCTs	119
5.18	Main effect plot of lag time as a function of HPMC and Coating levels	128
5.19	Interaction plot of lag time as a function of HPMC and Coating levels	129
5.20	Residual plot of lag time as a function of HPMC and Coating levels	129
5.21	The contour plot of lag time for selected HPMC and coating levels with corresponding design space	131

5.22	Drug release profile of optimized PRS CCT obtained with basket apparatus; 100 rpm agitation; 0.1 N HCl for first 2 h followed by pH 6.8 buffer; 500 mL volume; 37±0.5°C temperature	133
5.23	Lag time of PRS CCTs obtained using various dissolution conditions	134
5.24	SEM images of optimized PRS CCT before and after drug release study	136
5.25	FMEA analysis of PR formulation depicting RPN of failure modes before and after implementation of control strategy	139
5.26	Overlain HPLC chromatograms of 1-20 µg/mL MPR	148
5.27	HPLC calibration curve of MPR (1-20 µg/mL)	149
5.28	Drug release profile of MPR core tablets in pH 6.8 phosphate buffer; basket apparatus; 100 rpm; 500 mL; 37.0±0.5°C.	152
5.29	Drug release profile of optimized MPR CCTs obtained with basket apparatus; 100 rpm agitation; 0.1 N HCl for first 2 h followed by pH 6.8 buffer; 500 mL volume; 37±0.5°C temperature	153
5.30	Lag time of MPR CCTs obtained using various dissolution conditions	154
5.31	Overlaid HPLC chromatograms of 2-30 µg/mL DIC	159
5.32	HPLC calibration curve of DIC (2-30 µg/mL)	160
5.33	Drug release profile of DIC core tablet in pH 6.8 phosphate buffer; basket apparatus; 100 rpm; 500 mL; 37.0±0.5°C.	164
5.34	Drug release profile of optimized DIC CCTs obtained with basket apparatus; 100 rpm agitation; 0.1 N HCl for first 2 h followed by pH 6.8 buffer; 500 mL volume; 37±0.5°C temperature	165
5.35	Lag time of DIC CCTs obtained using various dissolution conditions	166
5.36	Overlaid HPLC chromatograms of 2-30 µg/mL DIL	171
5.37	HPLC calibration curve of DIL (2-30 µg/mL)	172
5.38	Drug release profile of DIL core tablet in pH 6.8 phosphate buffer; basket apparatus; 100 rpm; 500 mL; 37.0±0.5°C.	176
5.39	Drug release profile of optimized DIL CCTs obtained with basket apparatus; 100 rpm agitation; 0.1 N HCl for first 2 h followed by pH 6.8 buffer; 500 mL volume; 37±0.5°C temperature	177
5.40	Lag time of DIL CCTs obtained using various dissolution conditions	178
5.41	Overlaid HPLC chromatograms of 0.25-10 µg/mL NIF	184
5.42	HPLC calibration curve of NIF (0.25-10 µg/mL)	185
5.43	DSC thermograms of (A) NIF, (B) NIF-COP binary system, (C) NIF-povidone K30 binary system, (D) NIF-PEG6000 binary system, (E) NIF-xylitol binary system, (F) NIF-mannitol binary system, (G) NIF-HPMC E5 binary system, (H) NIF-HPMC E15 binary system, (I) NIF-HPMC E50 binary system, (J) NIF-HPMC AS LF binary system	189
5.44	DSC thermograms of (A) NIF, (B) COP, (C) NIF-COP PM and (D) NIF-COP ASD	190
5.45	PXRD spectra of (A) NIF, (B) COP, (C) NIF-COP PM and (D) NIF-COP ASD	191

5.46	FTIR spectra of (A) NIF, (B) COP, (C) NIF-COP PM and (D) NIF-COP ASD.	192
5.47	Results of equilibrium solubility study of crystalline NIF and NIF ASD in various aqueous media	193
5.48	Drug release profile of NIF core tablets prepared using ASD as well as plain API in pH 6.8 phosphate buffer/water; basket apparatus; 100 rpm; 900 mL; 37.0±0.5°C.	194
5.49	Drug release profile of optimized NIF CCTs obtained with basket apparatus; 100 rpm agitation; 0.1 N HCl for first 2 h followed by pH 6.8 buffer; 900 mL volume; 37±0.5°C temperature.	195
5.50	Lag time of NIF CCT obtained using various dissolution conditions	196
5.51	Overlain HPLC chromatograms of 0.25-10 µg/mL LOR	201
5.52	HPLC calibration curve of LOR (0.25-10 µg/mL)	202
5.53	DSC thermograms of (A) LOR, (B) MEG, (C) HPMC E5, (D) LOR-MEG-HPMC E5 PM, and (E) LOR-MEG-HPMC E5 ASD	205
5.54	PXRD spectra of (A) LOR, (B) MEG, (C) HPMC E5, (D) LOR-MEG-HPMC E5 PM, and (E) LOR-MEG-HPMC E5 ASD	206
5.55	FTIR spectra of (A) LOR, (B) MEG, (C) HPMC E5, (D) LOR-MEG-HPMC E5 PM, and (E) LOR-MEG-HPMC E5 ASD	207
5.56	Results of equilibrium solubility study of crystalline LOR and LOR ASD in various aqueous media.	208
5.57	Drug release profile of core tablets of LOR ASD as well as LOR API in pH 6.8 phosphate buffer/water; basket apparatus; 100 rpm; 900 mL; 37.0±0.5°C.	209
5.58	Drug release profile of LOR CCTs obtained with basket apparatus; 100 rpm agitation; 0.1 N HCl for first 2 h followed by pH 6.8 buffer; 900 mL volume; 37±0.5°C temperature.	210
5.59	Lag time of LOR CCTs obtained using various dissolution conditions	211
5.60	Step-by-step development of compression-coated PR platform formulation	214
5.61	Holistic overview of developed compression-coated PR platform formulation	216
6.1	LC-MS chromatogram of 0.1 ng/mL DIC standard solution	231
6.2	LC-MS chromatogram of 1000 ng/mL DIC standard solution	231
6.3	LC-MS calibration curve of DIC (0.1-1000 ng/mL)	232
6.4	SEM images of coating thickness analysis of optimized PRS PCT	234
6.5	SEM images of optimized PRS PCT before and after drug release study	235
6.6	The lag time results of different PCTs	236
6.7	The lag time results of different PCTs obtained using 5% v/v alcohol in 0.1 N HCl for first 2 h followed by pH 6.8 phosphate buffer	237
6.8	Plasma concentration vs. time profile after oral administration of DIC PCT formulation and DIC IR formulation in NZW rabbits	239
7.1	Comparative summary of lag times obtained with CCT formulations and PCT formulations	251